Positives

• A patient with severe eosinophilic asthma reported a roughly 50% drop in exacerbations after starting subcutaneous dosing, alongside improved health-related quality of life NEJM.
  
  
• Patients in clinical trials saw fatigue scores improve over baseline by week 32, supporting the idea that lowering eosinophil-driven inflammation can lift energy Drugs.com.
  
  

Negatives

• A patient described feeling "wiped out" for four to five days after each injection along with terrible joint pain that she compared to having the flu Drugs.com.
  
  
• Common reactions reported included headache, injection site pain or burning, back pain, and persistent low-grade fatigue between doses Drugs.com.
  
  

Hurdles & Side Effects

• A patient with MCAS-pattern Long COVID reported that her allergist would not prescribe this anti-IL-5 agent because she lacked the elevated eosinophil count required by the asthma indication Drugs.com.
  
  
• A user described the every-four-week subcutaneous schedule and the need for either clinic visits or careful self-injection training as a recurring logistical chore Drugs.com.